PetVivo, a Leading Provider of Veterinary Biomedicals, Reports Results for Fiscal Q1 2027
PetVivo reported fiscal Q1 2027 revenue of $337,572, up 13.5% year-over-year, while narrowing its net loss to $1.74 million compared to the prior year. The company announced a transformative acquisition of R&D partner PiezoBioMembrane to advance functional biomaterials and launched the beta version of its PetVivo.ai platform, which targets high-margin recurring revenue.
Key figures
- Revenue
- 337572
- Cash
- 122633
- Weighted average shares
- 37055261
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.